RPbio알피바이오
314140 · KOSDAQ · ₩314140 · 알피바이오
₩5,270▼ ₩30 (0.57%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩136B | ₩124B | ₩151B | ₩138B |
| Cost of sales | ₩122B | ₩117B | ₩135B | ₩120B |
| Gross profit | ₩14B | ₩7.2B | ₩16B | ₩18B |
| Operating income | ₩5.1B | −₩694M | ₩6.6B | ₩9.6B |
| Net income | ₩4.7B | −₩907M | ₩5.4B | ₩4.3B |
| Net income to shareholders | ₩4.7B | −₩907M | ₩5.4B | ₩4.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩156B | ₩159B | ₩166B | ₩173B |
| Current assets | ₩58B | ₩61B | ₩68B | ₩81B |
| Cash and equivalents | ₩9.8B | ₩14B | ₩3.2B | ₩17B |
| Total liabilities | ₩49B | ₩57B | ₩63B | ₩82B |
| Current liabilities | ₩44B | ₩51B | ₩57B | ₩79B |
| Borrowings | ₩16B | ₩25B | ₩25B | ₩35B |
| Total equity | ₩107B | ₩102B | ₩103B | ₩91B |
| Shareholders' equity | ₩107B | ₩102B | ₩103B | ₩91B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | ₩12B | ₩14B | ₩11B | ₩1.2B |
| Capital spending | ₩5.2B | ₩5.9B | ₩11B | ₩5.1B |
| Free cash flow | ₩7.3B | ₩7.7B | −₩543M | −₩4B |
| Dividends paid | — | ₩432M | — | — |
Consolidated where available. Amounts in won.
Also known as: RPbio / 알피바이오 / 314140 / KRX:314140
Source: KRX statistical information